市场医学维度浅析传统药企创新药研发

  • 打印
  • 收藏
收藏成功

摘 要 本文主要以肿瘤治疗领域为例简要论述在药品市场准入、创新药审评审批的新形势下,结合生物医学、转化医学及创新药临床价值相关内容,传统药企开展创新药研发所面临的机遇和应对策略,持续进行临床价值为导向的药物研发,以便上市更多解决未满足临床需求的创新药。

关键词 创新药研发 药物靶点 转化医学 临床价值

中图分类号:F425 文献标志码:C 文章编号:1006-1533(2022)15-0070-04

引用本文 何军芳. 市场医学维度浅析传统药企创新药研发[J]. 上海医药, 2022, 43(15): 70-73.

Brief analysis of innovative drug R&D of traditional pharmaceutical enterprise via marketing and medical dimension

HE Junfang

(Shanghai Xudonghaipu Pharmaceutical Co., Ltd., Shanghai 201206, China)

ABSTRACT Taking the field of oncology therapy as an example and combining biological medicine, translational medicine and the clinical value of innovative drugs, this article briefly discusses the opportunities and related strategies for traditional pharmaceutical enterprises to carry out innovative drug R&D, proceed clinical value-oriented drug R&D so as to launch more innovative drugs solving unmet clinical need under the new situation of drug market access and innovative drug review and approval.

KEY WORDS innovative drug R&D; drug target; translational medicine; clinical value

中国作为一个仿制药大国,国内传统药企的研发能力普遍体现为低水平仿制,创新能力不足。(剩余7371字)

monitor